Glycopeptide-based classification of erythropoietin biopharmaceuticals by microseparation techniques coupled to mass spectrometry and multivariate analysis.
This study highlights significant glycosylation differences among rhEPO biopharmaceuticals, which may impact their quality and assessment as biosimilars.
Where it sits
this study against the rest of the erythropoietin (epo) corpusSummary and findings
This study characterized three recombinant human erythropoietin (rhEPO) biopharmaceuticals using microseparation techniques and mass spectrometry. The analysis revealed differences in glycopeptide glycoforms among the products. The findings suggest potential applications in quality control and biosimilar assessment.
Abstract
In the present study, a bottom-up approach was followed to characterize three recombinant human erythropoietin (rhEPO) biopharmaceuticals: two commercially available drugs (EPO cim and EPO crs) and one currently under clinical evaluation for neurodegenerative diseases (NeuroEPO plus). After tryptic digestion, the resulting glycopeptides were analyzed using two complementary microseparation techniques: capillary electrophoresis and capillary liquid chromatography, both coupled to mass spectrometry (CE-MS and capLC-MS, respectively). These techniques enabled the detection of glycopeptide glycoforms displaying different degrees of sialylation and branching. CE-MS provided faster analyses and higher peak efficiency, whereas capLC-MS offered greater sensitivity, allowing the identification of a larger number of glycoforms. Given the complexity of the generated datasets, unsupervised and supervised multivariate data analysis was applied to explore glycosylation differences among the biopharmaceuticals and facilitate sample classification. Principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA) achieved clear differentiation of the three rhEPOs and revealed batch-to-batch variability with both microseparation techniques. In addition, the glycopeptide glycoforms that most strongly contributed to the product differentiation were identified. Specifically, EPO cim and EPO crs displayed higher relative abundances of tri- and tetra-sialylated structures, whereas NeuroEPO plus was characterized by a greater proportion of low-sialylated glycoforms. Moreover, EPO cim and EPO crs mainly differed in the relative abundance of N-glycolylneuraminic acid-containing glycoforms at O<sub>126</sub> and the relative abundance of glycoforms containing additional lactosamine units at N<sub>83</sub> despite being considered very similar rhEPOs. These results demonstrated that the established methodologies show great potential for applications in quality control, biosimilar assessment, and the characterization of glycoprotein-based therapeutics.
Background
This paper addresses the characterization of recombinant human erythropoietin (rhEPO) biopharmaceuticals, which are critical in treating conditions like anemia. Prior research has indicated variability in glycosylation patterns among biopharmaceuticals, which can affect their efficacy and safety. Understanding these differences is essential for quality control and regulatory assessment.
Methods
The study employed a bottom-up approach to analyze three rhEPO products: EPO cim, EPO crs, and NeuroEPO plus. Microseparation techniques, specifically capillary electrophoresis and capillary liquid chromatography, were coupled with mass spectrometry to analyze glycopeptides after tryptic digestion. Unsupervised and supervised multivariate data analysis techniques, including PCA and PLS-DA, were utilized to differentiate the products.
Results
The analysis revealed clear differentiation among the three rhEPOs. EPO cim and EPO crs had higher relative abundances of tri- and tetra-sialylated glycoforms, while NeuroEPO plus had a greater proportion of low-sialylated glycoforms. Specific differences were noted in the glycoforms at O126 and N83 between EPO cim and EPO crs.
Interpretation
The findings align with previous studies indicating glycosylation variability among biopharmaceuticals, which can influence their therapeutic profiles. While the statistical differentiation is noted, the clinical significance of these glycoform variations remains unclear without further context on their functional implications. Limitations include the lack of detailed numeric data and sample sizes, which may affect the reliability of the conclusions drawn.
Key findings
- EPO cim and EPO crs displayed higher relative abundances of tri- and tetra-sialylated structures.
- NeuroEPO plus was characterized by a greater proportion of low-sialylated glycoforms.
- EPO cim and EPO crs differed in the relative abundance of N-glycolylneuraminic acid-containing glycoforms at O126.
- EPO cim and EPO crs differed in the relative abundance of glycoforms containing additional lactosamine units at N83.
Limitations
- Not reported in abstract.
- No specific sample sizes provided.
- Lack of clinical outcome data.
- Focus on laboratory techniques without direct human data.